Effectiveness comparison of patients with hepatitis C virus genotypes 1 or 4 therapies

IF 1.7 Q2 PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH Clinical Epidemiology and Global Health Pub Date : 2025-01-01 Epub Date: 2024-12-13 DOI:10.1016/j.cegh.2024.101880

Abdullah Althemery , Abdulrahman Alturaiki , Rawan Alanazi , Nawal Almotairi , Manal Aljohani , Khalefa Althiab , Abdullah Alfaifi

{"title":"Effectiveness comparison of patients with hepatitis C virus genotypes 1 or 4 therapies","authors":"Abdullah Althemery , Abdulrahman Alturaiki , Rawan Alanazi , Nawal Almotairi , Manal Aljohani , Khalefa Althiab , Abdullah Alfaifi","doi":"10.1016/j.cegh.2024.101880","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>HCV is a global threat and can lead to major complications. The aim of this study was to compare the rate of achieving SVR12 from sofosbuvir-based therapy versus paritaprevir-based therapy in patients with HCV genotypes 1 or 4 in the Kingdom of Saudi Arabia.</div></div><div><h3>Methods</h3><div>This study was a retrospective cohort design conducted between January 2016 and January 2019; Participants were classified into sofosbuvir-based therapy (SBT) or paritaprevir-based therapy (PBT). Also, HCV specific genotype was examined: genotype 1, genotype 4, or mixed genotypes. A series of descriptive statistics were designed to compare patient characteristics. Significant predictors of SVR12 were identified using a stepwise logistic regression analysis.</div></div><div><h3>Results</h3><div>A total of 387 patients (294 on SBT; 93 on PBT) were included. The two groups were similar in most predisposing factors. 25.58 % of the overall sample reported previous treatment failure. Five predictors were identified that influence the achievement SVR12: sex, HCV type, interruption of therapy, alanine transaminase level, and hemoglobin level.</div></div><div><h3>Conclusions</h3><div>Saudi patients with HCV infection have a higher incidence of having genotype 4. In addition, both treatment regimens were associated with high percentages of attaining SVR at 12 weeks. More research is needed, particularly regarding the role of mixed genotypes in treatment outcomes.</div></div>","PeriodicalId":46404,"journal":{"name":"Clinical Epidemiology and Global Health","volume":"31 ","pages":"Article 101880"},"PeriodicalIF":1.7000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Epidemiology and Global Health","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2213398424003774","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/12/13 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH","Score":null,"Total":0}

引用次数: 0

Abstract

Background

HCV is a global threat and can lead to major complications. The aim of this study was to compare the rate of achieving SVR12 from sofosbuvir-based therapy versus paritaprevir-based therapy in patients with HCV genotypes 1 or 4 in the Kingdom of Saudi Arabia.

Methods

This study was a retrospective cohort design conducted between January 2016 and January 2019; Participants were classified into sofosbuvir-based therapy (SBT) or paritaprevir-based therapy (PBT). Also, HCV specific genotype was examined: genotype 1, genotype 4, or mixed genotypes. A series of descriptive statistics were designed to compare patient characteristics. Significant predictors of SVR12 were identified using a stepwise logistic regression analysis.

Results

A total of 387 patients (294 on SBT; 93 on PBT) were included. The two groups were similar in most predisposing factors. 25.58 % of the overall sample reported previous treatment failure. Five predictors were identified that influence the achievement SVR12: sex, HCV type, interruption of therapy, alanine transaminase level, and hemoglobin level.

Conclusions

Saudi patients with HCV infection have a higher incidence of having genotype 4. In addition, both treatment regimens were associated with high percentages of attaining SVR at 12 weeks. More research is needed, particularly regarding the role of mixed genotypes in treatment outcomes.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

1型和4型丙型肝炎病毒治疗的疗效比较

dhcv是一种全球性威胁，可导致重大并发症。本研究的目的是比较沙特阿拉伯王国1型或4型HCV患者使用索非布韦为基础的治疗与paritaprevir为基础的治疗实现SVR12的比率。方法本研究采用回顾性队列设计，于2016年1月至2019年1月进行；参与者被分为以索非布韦为基础的治疗（SBT）或以paritaprevir为基础的治疗（PBT）。此外，还检测了HCV特异性基因型：基因1型、基因4型或混合基因型。设计了一系列描述性统计来比较患者的特征。采用逐步逻辑回归分析确定SVR12的显著预测因子。结果共387例患者(SBT组294例；93页（PBT）。两组在大多数易感因素上相似。25.58%的总样本报告了先前的治疗失败。确定了影响SVR12实现的五个预测因素：性别、HCV类型、治疗中断、丙氨酸转氨酶水平和血红蛋白水平。结论沙特HCV感染患者具有较高的基因4型发生率。此外，两种治疗方案都与12周时SVR的高百分比相关。需要更多的研究，特别是关于混合基因型在治疗结果中的作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Clinical Epidemiology and Global Health PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH-

CiteScore

4.60

自引率

7.70%

发文量

218

审稿时长

66 days

期刊介绍： Clinical Epidemiology and Global Health (CEGH) is a multidisciplinary journal and it is published four times (March, June, September, December) a year. The mandate of CEGH is to promote articles on clinical epidemiology with focus on developing countries in the context of global health. We also accept articles from other countries. It publishes original research work across all disciplines of medicine and allied sciences, related to clinical epidemiology and global health. The journal publishes Original articles, Review articles, Evidence Summaries, Letters to the Editor. All articles published in CEGH are peer-reviewed and published online for immediate access and citation.